The gut mucosal barrier plays an important role in maintaining a delicate immune homeostasis. The pathogenesis of inflammatory bowel disease (IBD) is considered to involve a defective mucosal immunity along with a genetic predisposition. Recent views have suggested an excessive response to components of the gut microbiota in IBD. A condition of "dysbiosis", with alterations of the gut microbial composition, has been observed in patients with IBD. In this article, the author review recent studies of gut microbiota in IBD, particularly the importance of the gut microbiota in the pathogenesis of pediatric IBD. (Pediatr Gastroenterol Hepatol Nutr 2013; 16: 17∼21)
INTRODUCTION
Different genetic, immunologic, and environmental factors are implicated in the pathogenesis of inflammatory bowel disease (IBD). Recent views have suggested that patients with IBD may exhibit an excessive response to components of the gut microbiota. The gut mucosal barrier plays an important role in maintaining a delicate immune homeostasis. An inadequate immune response or overreaction of the immune system against food antigens (Ag) or components of the commensal flora can be a threat to this homeostasis. The human gut contains as many as 10 14 individual bacteria, comprising more than 1,000 different species. The most abundant bacteria phyla found in the large intestine of healthy adults are gram-negative Bacteroidetes and gram positive Firmicutes [1] . The intestinal microbiota are considered to act as a "metabolic organ", by deriving energy from nutrients that escape digestion in the upper gut. Moreover, the microbiota are considered to exert a barrier effect against pathogens in the intestinal mucosa. Germ-free animals do not develop enterocolitis when raised under germ-free conditions. However, when the animals are exposed to microbiota, mild to severe enterocolitis develops [2] . These results indicate the importance of gut microbiota in the pathogenesis of IBD.
DYSBIOSIS AND ABNORMAL IMMUNE RESPONSE
The concept of "dysbiosis" was introduced many
Pediatr Gastroenterol Hepatol Nutr decades ago, and was initially defined as an increase of enteric pathogen and decrease of commensal bacteria; however neither its biologic basis nor the concept of normal microbial balance has been defined. Technical development from a culture-dependent era to metagenomics has led to advances in the study of intestinal microbiota. The healthy host has an immune defense mechanism and tolerance toward microbe, and maintains immune homeostasis. [17] . Clostridium difficile, Entamoeba histolytica, Campylobacter, adenovirus, rotavirus, and mycoplasma were not primary causes, but could be associated with relapse. C. difficile was detected in 10-20% of patients with reactivated IBD [18] .
In total, the 20-25% of patients with IBD develop symptoms during childhood. Genetic factors are more influential than exogenous factors in children. In particularly, infants have immature mucosal immune systems and the intestinal microbiota composition is constantly changing. Few studies are available in pediatric patients with IBD. Recently, Michail et al. [19] reported decreased diversity of microbes in the feces of 27 children with ulcerative colitis. In children, depletion of Firmicutes, Verrucomicrobiae, and Lentisphaerae was prominent, a finding that was not different from the data of adults. It is possible that because most of the patients examined were adolescents, further study is needed in infants and young children. Michail et al. also reported that the decreased diversity of microbes was more prominent in the steroid non-responder group than in the steroid responder group.
MICROBIOTA AND GENETIC PREDIS-POSITION
Host genetics can contribute to dysbiosis.
Mutations in specific genes can lead to abnormal immune regulation, and in turn, may affect microbial composition. The importance of genetic predisposition for the development of IBD is well known. Since the discovery in 2001 that polymorphisms in the NOD2/CARD15 gene predispose to Crohn's disease in Caucasians [20] , genome-wide association studies have identified at least 70 susceptibility loci for Crohn's disease and 40 loci for ulcerative colitis. NOD2 is an intracellular pathogen-recognition receptor for bacterial muramyl dipeptide within mononuclear phagocytes and intestinal epithelial cells. ATG16L1 and IRGM genes act as susceptibility factors that mediate autophagy, which is a degradation system that delivers intracellular debris to lysosomes and contributes to the elimination of intracellular bacteria. A number of the candidate genes are of interest with regard to their influence on acute inflammatory response, including those associated with mucosal barrier function, cytokines or their related proteins (IL-10, IL-19, IL-27, IL-1RL1, IL-2RA, IL-12RL2, and IL-18R1), and chemokines (CCL 2 and CCL7). Almost all candidate genes participate in the host immune and adaptive response to microbial organisms and in the maintenance of homeostasis [21] . NOD2 variants (L1007X, R702W, G908R) and a ATG16L1 variant (T300A) were reportedly associated with dysbiosis in resected tissue from IBD patients, with decreases in Clostridium and in-creases in other bacteria in Crohn's disease and ulcerative colitis [22] . No associations were observed between NOD2 variants, the presence of MAP, and incidence of IBD [23] .
CONCLUSION
Dysbiosis is an important immunologic pathogenenic process in IBD. Changes of intestinal microbiota through genetics and environment (such as diet, infections or antibiotics) may contribute to defective host immune response. Dysbiosis and immune dysregulation might have a greater influence in young children than adolescents or adults. However, it is not clear whether dysbiosis contributes to the development of IBD or is instead a consequence of the disease.
Despite the importance of microbiota, antibiotics were not effective in the treatment of IBD, except in specific circumstances. Fecal transplantation has been attempted for fulminant and refractory C. difficile and in a few patients with IBD [24] . Further study is needed to evaluate the diagnostic and therapeutic implications in IBD.
